Targeting tumoral hypoxia: Finding opportunity in complexity

Future Oncology

Volumn 8, Issue 9, 2012, Pages 1065-1068

  Dhani, Neesha ^a   Milosevic, Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

functional imaging; microenvironmental targeting; nitroimidazole hypoxia markers; personalized medicine; tumor heterogeneity; tumoral hypoxia

Indexed keywords

BIOLOGICAL MARKER; NITROIMIDAZOLE; OXYGEN; PIMONIDAZOLE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MEDICINE; CANCER RADIOTHERAPY; CANCER SURGERY; COST; DNA REPAIR; FIBROBLAST; GENOMICS; HUMAN; HYPOXIA; HYPOXIC CELL; KNOWLEDGE; MEDICINE; NEOPLASM; NUTRIENT; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCIENTIST; TREATMENT RESPONSE; TUMOR GROWTH; TUMORAL HYPOXIA;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; NEOPLASMS; OXYGEN CONSUMPTION; TUMOR MICROENVIRONMENT;

EID: 84867091487     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.100     Document Type: Review

References (22)

1. Schilsky R. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9(5), 363-366 (2010).
2. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
3. Kleeff J, Beckhove P, Esposito I et al. Pancreatic cancer microenvironment. Int. J. Cancer 121(4), 699-705 (2007).
4. Hiscox S, Barrett-Lee P, Nicholson R. Therapeutic targeting of tumor-stroma interactions. Expert Opin Ther. Targets 15(5), 609-621 (2011).
5. Bristow R, Hill R. Hypoxia and metabolism: hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8(3), 180-192 (2008).
6. Brown J, Wilson W. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4(6), 437-447 (2004).
7. Overgaard J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25(26), 4066-4074 (2007).
8. Rischin D, Peters L, Fisher R et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23(1), 79-87 (2005).
9. Janku F, Wheler J, Westin S et al. PI3K/AKT/ mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30(8), 777-782 (2012).
10. Beck R, Roper B, Carlsen J et al. Pretreatment 18F-FAZA PET predicts success of hypoxiadirected radiochemotherapy using tirapazamine. J. Nucl. Med. 48(6), 973-980 (2007).
11. Rischin D, Hicks R, Fisher R et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 24(13), 2098-2104 (2006).
12. Wong R, Fyles A, Milosevic M, Pintilie M, Hill R. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumor variability, probe position, and track depth. Int. J. Radiat. Oncol. Biol. Phys. 39(2), 405-412 (1997).
13. Iakovlev V, Pintilie M, Morrison A, Fyles A, Hill R, Hedley D. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab. Invest. 87(12), 1206-1217 (2007).
14. Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M, Hill R. Heterogeneity and power in clinical biomarker studies. J. Clin. Oncol. 27(9), 1517-1521 (2009).
15. Bussink J, Kaanders J, Van Der Kogel A. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother. Oncol. 67(1), 3-15 (2003).
16. Moon E, Brizel D, Chi J, Dewhirst M. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 9(8), 1237-1294 (2007).
17. Cobb LM, Hacker T, Nolan J. NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole. Br. J. Cancer 61(4), 524-529 (1990).
18. Dewhirst M, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8(6), 425-437 (2008).
19. Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 100(8), 1366-1373 (2009).
20. Meng F, Evans JW, Bhupathi D et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH?302. Mol. Cancer Ther. 11(3), 740-751 (2012).
21. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother. Oncol. 102(1), 122-129 (2011).
22. Toustrup K, Sorensen BS, Nordsmark M et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 71(17), 5923-5931 (2011).